期刊
EMBO MOLECULAR MEDICINE
卷 8, 期 2, 页码 117-138出版社
WILEY
DOI: 10.15252/emmm.201505557
关键词
demethylating agent; epigenetics; HDACIs; HIV latency; HIV reservoir
资金
- Belgian Fund for Scientific Research (FRS-FNRS, Belgium)
- ANRS (France Recherche Nord&Sud Sida-HIV Hepatites)
- Fondation Roi Baudouin
- NEAT Program
- Walloon Region (the Excellence Program Cibles)
- Walloon Region (Fond de maturation program)
- Institut Universitaire de France (IUF)
Reactivation of HIV gene expression in latently infected cells together with an efficient cART has been proposed as an adjuvant therapy aimed at eliminating/decreasing the reservoir size. Results from HIV clinical trials using deacetylase inhibitors (HDACIs) question the efficiency of these latency-reversing agents (LRAs) used alone and underline the need to evaluate other LRAs in combination with HDACIs. Here, we evaluated the therapeutic potential of a demethylating agent (5-AzadC) in combination with clinically tolerable HDACIs in reactivating HIV-1 from latency first invitro and next exvivo. We showed that a sequential treatment with 5-AzadC and HDACIs was more effective than the corresponding simultaneous treatment both invitro and exvivo. Interestingly, only two of the sequential LRA combinatory treatments tested induced HIV-1 particle recovery in a higher manner than the drugs alone exvivo and at concentrations lower than the human tolerable plasmatic concentrations. Taken together, our data reveal the benefit of using combinations of 5-AzadC with an HDACI and, for the first time, the importance of treatment time schedule for LRA combinations in order to reactivate HIV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据